TechCrunch Disrupt Finalist and World Changing Idea in Fast Company, Parallel is a precision health company pioneering Microbiome Dermatology™ using microbial genomics, big data, and ML/AI.
Current Status
We are currently in our pilot launch phase:
CAC: $20
AOV: $200
LTV: $1200+
Revenue to Date: $200k
Problem or Opportunity
Dermatology is a visual medical practice, where diagnosis is in the hands of dermatologists. Compared to other sectors of health, dermatology is behind in advanced testing. Dermatologists are also the #1 prescribers of antibiotics. The standard of care is such that for an issue like persistent acne, a patient will go through several rounds of antibiotics or be on long-term antibiotics with no true cure except for Accutane, which has dire side effects like mental health issues, joint pain, aging. We believe that the health and cosmetics industry can do better for customers and patients alike.
Solution (product or service)
Parallel Health offers cutting-edge skin microbiome testing followed by personalized solutions for acne, aging, discoloration, eczema, hidradenitis suppurative, and rosacea. Our flagship product is the MD-03 Protocol™, which is a customized plan that comes with skin microbiome testing twice a year, unlimited doctor visits via zoom and text, microbiome friendly reset pack, and a monthly delivery of your custom Active Phage Serum. Parallel is a fully licensed telehealth practice and 100% HSA/FSA eligible.
Business model
We are DTC and B2B2C (clinics). The sales of our products feed into data acquisition to fuel our predictive health engine.
Incubation/Acceleration programs accomplishment
Illumina Accelerator
StartX (Stanford)
MedTech Innovator
Health Engine (UC Berkeley)
